Showing results (341-350 of 384) with videos related to
Sort By:
Pageof 39
Breast Cancer Research and Treatment|October 24, 2023
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancerTakayuki Iwamoto, Naoki Niikura, Kenichi Watanabe, et al.Breast (Edinburgh, Scotland)|April 30, 2026
Health-related quality of life with pertuzumab retreatment: Secondary analysis of the PRECIOUS trialNaruto Taira, Yutaka Yamamoto, Hiroji Iwata, et al.Breast Cancer Research and Treatment|January 5, 2024
Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinomaSaki Nakagawa, Minoru Miyashita, Ichiro Maeda, et al.Cancers|September 10, 2021
Targeting Amino Acid Metabolic Reprogramming via L-Type Amino Acid Transporter 1 (LAT1) for Endocrine-Resistant Breast CancerHaruhiko Shindo, Narumi Harada-Shoji, Akiko Ebata, et al.Circulation|March 6, 2023
Pulsed Field Ablation for the Treatment of Atrial Fibrillation: PULSED AF Pivotal TrialAtul Verma, David E Haines, Lucas V Boersma, et al.Journal of Human Genetics|September 17, 2024
Nationwide survey of the secondary findings in cancer genomic profiling: survey including liquid biopsySaki Shimada, Takahiro Yamada, Akari Minamoto, et al.International Heart Journal|November 19, 2019
Feasibility of Uninterrupted Direct Oral Anticoagulants with Temporary Switching to Dabigatran ("Dabigatran Bridge") for Catheter Ablation of Atrial FibrillationDaisetsu Aoyama, Shinsuke Miyazaki, Kanae Hasegawa, et al.Cancers|April 25, 2019
Automated Quantification of Extranuclear ERα using Phosphor-integrated Dots for Predicting Endocrine Therapy Resistance in HR+/HER2- Breast CancerZhaorong Guo, Hiroshi Tada, Narufumi Kitamura, et al.Heart Rhythm|July 27, 2025
Efficacy and safety of catheter ablation for paroxysmal atrial fibrillation: A comparison of first-line vs second-line therapyJun Oikawa, Hidehira Fukaya, Koshiro Kanaoka, et al.Japanese Journal of Clinical Oncology|July 19, 2018
A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS studyYutaka Yamamoto, Hiroji Iwata, Takayuki Ueno, et al.Pageof 39